WO2024002235 - ANTI-EGFR/MET ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/002235
Publication Date
04.01.2024
International Application No.
PCT/CN2023/103811
International Filing Date
29.06.2023
Title **
[English]
ANTI-EGFR/MET ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-EGFR/MET ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
HAN, Yanfei
SHANG, Chengzhang
LIU, Baihong
YANG, Yi
SHEN, Yuelei
Priority Data
PCT/CN2022/102231
29.06.2022
CN
PCT/CN2022/108838
29.07.2022
CN
PCT/CN2022/116678
02.09.2022
CN
PCT/CN2022/141416
23.12.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6466 | |
| EPO | Filing, Examination, Granting | 137210 | |
| Japan | Filing, Examination, Granting | 5133 | |
| South Korea | Filing, Examination, Granting | 10658 | |
| USA | Filing, Examination, Granting | 37690 |
Total:
197,157
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided is antigen-binding protein constructs (e.g., bispecific antibodies, antigen-binding fragments thereof, or ADCs), wherein the antigen-binding protein constructs specifically bind to two different antigens (e.g., EGFR and MET).[French]
L'invention concerne des constructions de protéine de liaison à l'antigène (par exemple, des anticorps bispécifiques, des fragments de liaison à l'antigène de ceux-ci, ou des ADC), les constructions de protéine de liaison à l'antigène se liant de manière spécifique à deux antigènes différents (par exemple, EGFR et MET).